Technical Analysis for ADAP - Adaptimmune Therapeutics plc
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical ADAP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Dec 14 | 180 Bearish Setup | Bearish Swing Setup | 0.00% |
| Dec 14 | Outside Day | Range Expansion | 0.00% |
| Dec 13 | Narrow Range Bar | Range Contraction | -3.73% |
| Dec 13 | NR7 | Range Contraction | -3.73% |
| Dec 13 | Inside Day | Range Contraction | -3.73% |
| Dec 12 | Fell Below 20 DMA | Bearish | -1.71% |
| Dec 12 | New 52 Week Low | Weakness | -1.71% |
| Dec 12 | Lower Bollinger Band Touch | Weakness | -1.71% |
| Dec 11 | 20 DMA Support | Bullish | -10.26% |
| Dec 11 | Outside Day | Range Expansion | -10.26% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-06
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ADAP news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 14.625 |
| 52 Week Low | 4.82 |
| Average Volume | 654,824 |
| 200-Day Moving Average | 10.3834 |
| 50-Day Moving Average | 7.5643 |
| 20-Day Moving Average | 5.596 |
| 10-Day Moving Average | 5.723 |
| Average True Range | 0.5272 |
| ADX | 24.31 |
| +DI | 17.0592 |
| -DI | 29.7428 |
| Chandelier Exit (Long, 3 ATRs ) | 4.9884 |
| Chandelier Exit (Short, 3 ATRs ) | 6.4016 |
| Upper Bollinger Band | 6.2475 |
| Lower Bollinger Band | 4.9445 |
| Percent B (%b) | 0.17 |
| BandWidth | 23.284489 |
| MACD Line | -0.4804 |
| MACD Signal Line | -0.5711 |
| MACD Histogram | 0.0907 |
| Fundamentals | Value |
|---|---|
| Market Cap | 482.56 Million |
| Num Shares | 93.5 Million |
| EPS | -0.99 |
| Price-to-Earnings (P/E) Ratio | -5.21 |
| Price-to-Sales | 39.39 |
| Price-to-Book | 2.97 |
| PEG Ratio | 0.17 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.58 | ||||
| Resistance 3 (R3) | 5.61 | 5.49 | 5.51 | ||
| Resistance 2 (R2) | 5.49 | 5.39 | 5.48 | 5.49 | |
| Resistance 1 (R1) | 5.33 | 5.32 | 5.27 | 5.30 | 5.46 |
| Pivot Point | 5.21 | 5.21 | 5.19 | 5.20 | 5.21 |
| Support 1 (S1) | 5.05 | 5.11 | 4.99 | 5.02 | 4.86 |
| Support 2 (S2) | 4.93 | 5.04 | 4.92 | 4.83 | |
| Support 3 (S3) | 4.77 | 4.93 | 4.81 | ||
| Support 4 (S4) | 4.74 |
